SCHEMBL12026454

SCHEMBL12026454

CC(C)N1CCC(CC(=O)N2CCN(C)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.43
▸ HRH3 Q9Y5N1 3/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ CYP2D6 P10635 1/20 0.40
▸ CACNA2D1 P54289 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ CACNB1 Q02641 1/20 0.39
▸ CACNA1C Q13936 1/20 0.39
▸ SMYD3 Q9H7B4 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ TPSAB1 Q15661 1/20 0.38
▸ TPSD1 Q9BZJ3 1/20 0.38
▸ TPSG1 Q9NRR2 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ ADAM10 O14672 1/20 0.37
▸ ERBB2 P04626 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25443839 0.92 HRH3 (0.48) NAMPTHRH3KCNH2CYP2D6TPSAB1
SCHEMBL18390493 0.86 NAMPT (0.51) NAMPTHRH3KCNH2CYP2D6TPSAB1
SCHEMBL12049756 0.86 NAMPT (0.50) NAMPTCACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL16838103 0.84 NAMPT (0.56) NAMPTSMYD3HTR1AGNAI3GNAO1
SCHEMBL14453896 0.84 HRH3 (0.45) NAMPTHRH3KCNH2CYP2D6TPSAB1
SCHEMBL24671513 0.84 ALDH1A1 (0.50) NAMPTHRH3KCNH2CYP2D6TPSAB1
SCHEMBL1913158 0.83 L3MBTL1 (0.42) NAMPTHRH3PIK3CAMTOR
SCHEMBL25443838 0.83 NAMPT (0.42) NAMPTHRH3KCNH2CYP2D6SMYD3
SCHEMBL17679889 0.81 HRH3 (0.39) HRH3KCNH2CYP2D6
SCHEMBL23603458 0.80 GNAI3 (0.45) NAMPTCACNA2D1CACNA1BCACNB1CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718803-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. (US) 2017-08-01 — — US disclosed
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2016-04-14 — — US disclosed
US-8957073-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. 2015-02-17 — — US disclosed
US-20140213572-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2014-07-31 — — US disclosed
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2011-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213572-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A NAMPT 212/4885HRH3 3292/4885KCNH2 3476/4885
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A NAMPT 212/4885HRH3 3292/4885KCNH2 3476/4885
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A NAMPT 212/4885HRH3 3292/4885KCNH2 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback